SLXN

2.74

3.86% -0.11

Handel nachbörslich: 2.50 -0.24 -8.76%

Silexion Therapeutics Corp (SLXN)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$2.85

Offen:

$2.81

24-Stunden-Volumen:

10,506

Relative Volume:

0.02

Marktkapitalisierung:

$2.91M

Einnahmen:

Nettoeinkommen (Verlust:

$-11.91M

KGV:

-0.309

EPS:

-8.8661

Netto-Cashflow:

$-10.83M

1W Leistung:

+7.45%

1M Leistung:

-41.33%

6M Leistung:

-86.95%

1J Leistung:

-97.76%

1-Tages-Spanne:

$2.64

$2.81

1-Wochen-Bereich:

$2.54

$2.85

52-Wochen-Spanne:

$2.31

$223.60

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Firmenname

Silexion Therapeutics Corp

Sektor

Healthcare (1094)

Branche

Biotechnology (615)

Telefon

972-8-6286005

Adresse

12 ABBA HILLEL ROAD, RAMAT GAN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

SLXN's Discussions on Twitter

Compare SLXN vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SLXN Silexion Therapeutics Corp	2.74	3.03M	0	-11.91M	-10.83M	-8.8661
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten

04:02 AM

Price to earnings forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView

04:02 AM

10:01 AM

Enterprise value to EBITDA forward of Silexion Therapeutics Corp – BOATS:SLXN - TradingView

10:01 AM

Jul 03, 2026

Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN

Jul 03, 2026

Jun 28, 2026

SLXN Q1 2026 Earnings: EPS Beat Highlights Narrower-than-Expected Loss Amid Development StageFinancial Summary - dars.gov.et

Jun 28, 2026

Jun 26, 2026

Price to sales forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Price to earnings forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Jun 24, 2026

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - Sahm

Jun 24, 2026

Silexion Therapeutics Warrants (SLXNW) Hold Flat at $0.03 as Range TightensComposite Profile - dars.gov.et

Jun 24, 2026

Form 13D/A Silexion Therapeutics Corp For: 23 June By Investing.com - Investing.com Australia

Jun 24, 2026

Jun 23, 2026

Silexion Therapeutics Says Germany Approves Phase 2/3 Trial of SIL204 in Pancreatic Cancer - marketscreener.com

Jun 23, 2026

Silexion Therapeutics Receives BfArM Approval to Initiate Phase 2/3 SIL204 Trial in Germany - Quiver Quantitative

Jun 23, 2026

Jun 22, 2026

[EFFECT] Silexion Therapeutics Corp SEC Filing - Stock Titan

Jun 22, 2026

SLXN Q1 2026 Earnings: Solid EPS Beat Highlights Cost Discipline Amid Pre-Revenue StageEarnings Risk Report - dars.gov.et

Jun 22, 2026

Jun 20, 2026

Silexion Therapeutics (SLXN) Slides 5.86% as Shares Approach Key Support at $2.59Oversold Bounce Ideas - dars.gov.et

Jun 20, 2026

Jun 19, 2026